Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipelineGlobeNewsWire • 12/24/25
Press Release: Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosisGlobeNewsWire • 12/24/25
Press Release: Sanofi's Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaGlobeNewsWire • 12/23/25
Press Release: Sanofi and Regeneron's Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaGlobeNewsWire • 12/23/25
Sanofi: Information concerning the total number of voting rights and shares - November 2025GlobeNewsWire • 12/22/25
Nine pharmaceutical companies including Bristol-Myers Squibb, GSK and Merck agreed to lower the prices that certain federal government programs and patients payWSJ • 12/19/25
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovationGlobeNewsWire • 12/19/25
SNY's Rare Disease Drug Efdoralprin Alfa Gets EMA's Orphan Drug TagZacks Investment Research • 12/18/25
Sanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments TranscriptSeeking Alpha • 12/17/25
South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with SanofiReuters • 12/15/25
Sanofi: Today's Tolebrutinib Setback Shouldn't Worry Shareholders - This Is WhySeeking Alpha • 12/15/25
Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease CollaborationBenzinga • 12/15/25
Dren Bio to collaborate with Sanofi to develop autoimmune disease therapies for up to $1.7 billionReuters • 12/15/25
Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion TherapyBusiness Wire • 12/15/25